Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain
- Conditions
- DepressionPain
- First Posted Date
- 2002-05-10
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 286
- Registration Number
- NCT00036335
Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder
- Conditions
- Depressive Disorder
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00036309
- Locations
- 🇺🇸
For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559), Durham, North Carolina, United States
A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury
- Conditions
- Respiratory Distress Syndrome, AdultAcute Lung Injury
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT00036062
Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 530
- Registration Number
- NCT00036088
EVA: Evista Alendronate Comparison
- Conditions
- Osteoporosis
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00035971
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559 or speak with your personal physician., Temple, Texas, United States
🇨🇦For additional information regarding investigative sites for this trial, contact the Clinical Trials Support center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Saskatoon, Saskatchewan, Canada
🇺🇸For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Madison, Wisconsin, United States
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2006-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT00035321
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. John, Canada
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
- Conditions
- Pancreatic NeoplasmsMetastases, Neoplasm
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00035035
Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
- Conditions
- DepressionSchizophreniaSchizoaffective Disorder
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 378
- Registration Number
- NCT00034801
A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
- Conditions
- Urologic NeoplasmsMetastases, Neoplasm
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00035061
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
- Conditions
- Osteoporosis, Postmenopausal
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2007-05-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 330
- Registration Number
- NCT00035256
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sainte -Foy, Quebec, Canada